Actelion

From WikiMD.org
Jump to navigation Jump to search

Actelion

Actelion (pronounced: ak-te-lee-on) is a pharmaceutical company that specializes in the discovery, development, and commercialization of innovative treatments to serve high unmet medical needs.

Etymology

The name "Actelion" is derived from the Latin word "actio" meaning action, and the Greek word "lion" meaning lion. This signifies the company's commitment to action and strength in the pharmaceutical industry.

History

Actelion was founded in 1997 by a group of scientists and clinicians who had previously worked at Roche, a multinational healthcare company. The founders wanted to create a company that would focus on the discovery and development of novel treatments for diseases with high unmet medical needs.

Products

Actelion has a diverse portfolio of products that treat a range of conditions, including pulmonary arterial hypertension (PAH), Gaucher's disease, and multiple sclerosis (MS). Some of their most well-known products include Tracleer, Opsumit, and Uptravi.

Research and Development

Actelion is committed to research and development, with a focus on discovering and developing innovative treatments for diseases with high unmet medical needs. The company has a strong pipeline of potential new therapies in various stages of clinical development.

Acquisition by Johnson & Johnson

In 2017, Actelion was acquired by Johnson & Johnson, one of the world's largest and most diverse healthcare companies. The acquisition has allowed Actelion to continue its focus on research and development while benefiting from the resources and global reach of Johnson & Johnson.

Related Terms

External links

Esculaap.svg

This WikiMD article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski